Mergers & Acquisitions ·
RedHill Biopharma regains ex-North America rights to RHB-102 from Hyloris for $200K fee
RDHLRedHill Biopharma Ltd.
RedHill Biopharma has regained all ex-North America rights to its proprietary drug candidate RHB-102 through a mutual agreement with Hyloris Pharmaceuticals SA that terminated their License & Development Agreement on October 15, 2026. As part of the termination, Hyloris paid RedHill a one-time break-up fee of $200,000. The company retains full worldwide rights to RHB-102, an extended-release ondansetron formulation for oncology support and GI indications, including GLP-1/GIP-associated intolerance, and will continue late-stage development while exploring potential partnerships. RedHill Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal disorders and cancer supportive care.